Abstract: Systems and methods for filtering materials from biologic fluids are discussed. Embodiments may be used to filter cerebrospinal fluid (CSF) from a human or animal subject. In an example, CSF is separated into a permeate and retentate using a tangential flow filter. The retentate is filtered again and then returned to the subject with the permeate. During operation of the system, various parameters may be modified, such as flow rate and waste rate.

Abstract: Systems and methods for filtering materials from biologic fluids are discussed. Embodiments may be used to filter cerebrospinal fluid (CSF) from a human or animal subject. In an example, CSF is separated into a permeate and retentate using a tangential flow filter. The retentate is filtered again and then returned to the subject with the permeate. During operation of the system, various parameters may be modified, such as flow rate and waste rate.

Abstract: Systems and methods for filtering materials from biologic fluids are discussed. Embodiments may be used to filter cerebrospinal fluid (CSF) from a human or animal subject. The method may include the steps of withdrawing fluid comprising CSF, filtering the volume into permeate and retentate by passing the fluid through a tangential flow filter, and returning the permeate to the subject. During operation of the system, various parameters may be modified, such as flow rate.

Abstract: Systems and methods for filtering materials from biologic fluids are discussed. Embodiments may be used to filter cerebrospinal fluid (CSF) from a human or animal subject. The method may include the steps of withdrawing fluid comprising CSF, filtering the volume into permeate and retentate by passing the fluid through a tangential flow filter, and returning the permeate to the subject. During operation of the system, various parameters may be modified, such as flow rate.

Abstract: Systems and methods for filtering materials from biologic fluids are discussed. Embodiments may be used to filter cerebrospinal fluid (CSF) from a human or animal subject. In an example, CSF is separated into a permeate and retentate using a tangential flow filter. The retentate is filtered again and then returned to the subject with the permeate. During operation of the system, various parameters may be modified, such as flow rate and waste rate.

Abstract: Systems and methods for filtering materials from biologic fluids are discussed. Embodiments may be used to filter cerebrospinal fluid (CSF) from a human or animal subject. In an example, CSF is separated into a permeate and retentate using a tangential flow filter. The retentate is filtered again and then returned to the subject with the permeate. During operation of the system, various parameters may be modified, such as flow rate and waste rate.

Abstract: Systems and methods for filtering materials from biologic fluids are discussed. Embodiments may be used to filter cerebrospinal fluid (CSF) from a human or animal subject. In an example, CSF is separated into a permeate and retentate using a tangential flow filter. The retentate is filtered again and then returned to the subject with the permeate. During operation of the system, various parameters may be modified, such as flow rate and waste rate.

Abstract: Systems and methods for filtering materials from biologic fluids are discussed. Embodiments may be used to filter cerebrospinal fluid (CSF) from a human or animal subject. The method may include the steps of withdrawing fluid comprising CSF, filtering the volume into permeate and retentate by passing the fluid through a tangential flow filter, and returning the permeate to the subject. During operation of the system, various parameters may be modified, such as flow rate.

Abstract: A system and method provide for detecting atrial arrhythmias within an implantable medical device capable of sensing and pacing at least an atrium of a heart. Arrhythmia of the atrium is detected. In response to detecting atrial arrhythmia, delivery of pacing signals to the atrium is inhibited under certain conditions. While delivery of the pacing signals to the atrium is inhibited, the detected arrhythmia of the atrium is confirmed during a period of further evaluation. Delivery of pacing signals to the atrium is enabled upon ceasing of the atrial arrhythmia. Inhibiting delivery of the pacing signals during atrial arrhythmia evaluation advantageously provides for an increase in the rate at which the detected arrhythmia is confirmed.

Abstract: A system and method provide for detecting atrial arrhythmias within an implantable medical device capable of sensing and pacing at least an atrium of a heart. Arrhythmia of the atrium is detected. In response to detecting atrial arrhythmia, delivery of pacing signals to the atrium is inhibited under certain conditions. While delivery of the pacing signals to the atrium is inhibited, the detected arrhythmia of the atrium is confirmed during a period of further evaluation. Delivery of pacing signals to the atrium is enabled upon ceasing of the atrial arrhythmia. Inhibiting delivery of the pacing signals during atrial arrhythmia evaluation advantageously provides for an increase in the rate at which the detected arrhythmia is confirmed.

Abstract: A system and method provide for detecting atrial arrhythmias within an implantable medical device capable of sensing and pacing at least an atrium of a heart. Arrhythmia of the atrium is detected. In response to detecting atrial arrhythmia, delivery of pacing signals to the atrium is inhibited under certain conditions. While delivery of the pacing signals to the atrium is inhibited, the detected arrhythmia of the atrium is confirmed during a period of further evaluation. Delivery of pacing signals to the atrium is enabled upon ceasing of the atrial arrhythmia. Inhibiting delivery of the pacing signals during atrial arrhythmia evaluation advantageously provides for an increase in the rate at which the detected arrhythmia is confirmed.

Abstract: Methods, systems, and apparatuses for ways of testing tags are provided. In an aspect of the present invention, an antenna is mounted in a cavity of a surface. The antenna transmits a test signal, such as a radio frequency (RF) test signal, to the antenna of an adjacent tag, to test the adjacent tag. In aspects, multiple cavities having antennas may be arranged in various ways in the surface, such as in a “checkerboard pattern” (e.g., diagonally positioned from each other), to test multiple tags in a web of tags simultaneously. In another aspect, tags that are not being tested may be held at an electrical voltage, such as a ground voltage, to disable the tags from responding to the test signals of other tags. For example, in an aspect, a vacuum system may be used to hold tags in a web of tags to the surface to hold antennas of the tags at the electrical voltage.

Abstract: Methods, systems, and apparatuses for testing radio frequency identification (RFID) tags are described. The tags are tested using a direct connection scheme, where a testing apparatus makes direct contact with a portion of a tag in order to perform a test on the tag. For example, the testing apparatus may read data from the tag to verify operation. Any number of tags may be tested at a time, including one tag at a time, or multiple tags in parallel.

Abstract: An implantable cardiac device detects a patient therapy request originating from external to the implantable device. A shock therapy delay period is timed in response to the detection of the patient therapy request. Atrial shock therapy is provided to the patient after expiration of the shock therapy delay period (if the presence of an ongoing atrial arrhythmia is detected). The patient therapy request may be provided by a patient activator including a magnet for operating a reed switch in the implanted device to provide the request. A patient activator including an input and receiver/transmitter circuitry may be employed to request the immediate providing of atrial shock therapy, and/or to set the duration the shock therapy delay period. By allowing specific delays to therapy after a therapy request, a patient can prepare for the requested therapy and thereby mitigate therapy discomfort.

Abstract: An implanted cardiac device detects an atrial arrhythmia and provides periodically updated atrial arrhythmia status as long as the arrhythmia is ongoing. A patient may request an indication of ongoing atrial arrhythmia status from external to the patient using a patient activator. The patient activator may include a magnet for closing a reed switch in the implanted device to provide the request or may provide the request over a telemetry link to the implanted device. The implanted device may provide the requested atrial arrhythmia status and other information in the form of an audible tone produced by the implanted device or as a message telemetered from the implanted device to the patient activator. The patient activator may include a tone detector and display for providing a visual indication of the atrial arrhythmia status indication. The magnet activator may also be employed to request or withhold atrial shock therapy.

Abstract: An apparatus and method is presented for treating patients with sinus node dysfunction who have apparently normal intrinsic AV conduction and thus do not require ventricular pacing unless there is an unexpected AV conduction failure. In one embodiment, a cardiac device with dual-chamber pacing capability is programmed to operate in a primary DDI (or DDI(R)) mode adjusted to pace only the atria if intrinsic AV conduction is intact and switch to a secondary DDD (or DDD(R)) mode upon detection of AV block.

Abstract: A system and method provides for inhibiting delivery of atrial therapy under certain conditions. Inhibiting delivery of atrial therapy involves developing atrial intervals and ventricular intervals from sensed atrial and ventricular events, respectively. An average atrial rate and an average ventricular rate is developed from a predetermined number of the atrial and ventricular intervals, respectively. Delivery of atrial therapy is inhibited if the average atrial rate fails to exceed the average ventricular rate by at least a predetermined factor.

Abstract: A system and method provide for detecting atrial arrhythmias within an implantable medical device capable of sensing and pacing at least an atrium of a heart. Arrhythmia of the atrium is detected. In response to detecting atrial arrhythmia, delivery of pacing signals to the atrium is inhibited under certain conditions. While delivery of the pacing signals to the atrium is inhibited, the detected arrhythmia of the atrium is confirmed during a period of further evaluation. Delivery of pacing signals to the atrium is enabled upon ceasing of the atrial arrhythmia. Inhibiting delivery of the pacing signals during atrial arrhythmia evaluation advantageously provides for an increase in the rate at which the detected arrhythmia is confirmed.

Abstract: Systems and methods implemented with an implantable medical device (IMD) are provided for performing cardiac testing while temporarily disabling all or selected antitachyarrhythmia therapy delivery capabilities of the device. An initiation signal indicative of initiation of a cardiac test, such as an electrophysiologic test, is received by the IMD. In response to the test initiation signal, a capability of delivering tachyarrhythmia therapy to a chamber of the heart is temporarily disabled. While the capability of delivering tachyarrhythmia therapy is disabled, the subject heart chamber is monitored in response to electrophysiologic testing. The capability of delivering tachyarrhythmia therapy is automatically re-enabled to ensure availability of tachyarrhythmia therapy after completion or interruption of the electrophysiologic test.

Abstract: A system and method provides for managing atrial ATP therapy in response to possible atrial lead dislodgment. An impedance of an atrial lead is measured for a particular patient. The measured impedance is compared with an impedance threshold developed for the particular patient. Atrial ATP therapy delivery is disabled in response to the measured impedance deviating from the impedance threshold by a predetermined factor. The impedance threshold may be developed from one or more atrial lead impedance measurements, and may also be characterized by a mean or a median of several atrial lead impedance measurements. The predetermined factor may be characterized by a percentage change, a fixed delta change, or both a percentage change and a fixed delta change in the measured impedance relative to the impedance threshold.